AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11429021
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (400 mg tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Trial: 8262130
Drug: Leuprolide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide plus flutamide (250 mg p.o. t.i.d.)
Trial: 4023977
Drug: Inhaled lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lignocaine
Trial: 24906665
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis for children with dilating VUR
Trial: 19883384
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) - Lindynette® and Cilest®
Trial: 19281738
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous calcitriol
Trial: 19281738
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral calcitriol
Trial: 17002607
Drug: HE2000 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HE2000 (50 mg)
Trial: 17002607
Drug: HE2000 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HE2000 (50 mg or 100 mg)
Trial: 20718734
Drug: Haem arginate
RxNorm normalized name: Haem arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haem arginate (HA) infusion
Trial: 16446690
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (CS) supplementation (3,600 mg x day‐1 for 14 days)
Trial: 1328358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormonal therapy)
Trial: 2754149
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate aerosol (MPA) inhalation and placebo injection
Trial: 2754149
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection (EPI) and inhaled placebo
Trial: 2754149
Drug: Crossover comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover comparison regimen after initial treatment
Trial: 1278718
Drug: Control (secretin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (secretin and cholecystokinin without drugs)
Trial: 2841841
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g soy polysaccharide
Trial: 2841841
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g soy polysaccharide
Trial: 17986035
Drug: 0.2% solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% solutions
Trial: 17986035
Drug: 0.25% solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% solutions
Trial: 15659490
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation, repeated after 6 weeks.
Trial: 15659490
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination therapy with doxorubicin and paclitaxel (AT).
Trial: 10194129
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell receptor (TCR) variable (V) region expression assessment using monoclonal antibodies specific for different V region families (alpha or beta) in combination with anti‐CD4 or anti‐CD8.
Trial: 7749881
Drug: Atorvastatin 2.5
RxNorm normalized name: amlodipine-atorvastatin 2.5 mg-10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 2.5 mg
Trial: 380736
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metronidazole as an intravenous infusion during the operation
Trial: 29101708
Drug: PBMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT with dose of 15 J per site
Trial: 29101708
Drug: PBMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT with doses of 30 J per site
Trial: 29101708
Drug: PBMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT with doses of 60 J per site
Trial: 24446755
Drug: 20 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 sessions of NB‐UVB treatment before transplantation
Trial: 24446755
Drug: 30 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 sessions of NB‐UVB treatment after transplantation
Trial: 24446755
Drug: 20 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 sessions of NB‐UVB treatment before transplantation and 30 sessions after transplantation
Trial: 24446755
Drug: Only transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only transplantation (no NB‐UVB treatment)
Trial: 22055478
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition supplemented with L-glutamine (30 g) for 2 days
Trial: 22055478
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition with calcium caseinate (30 g) for 2 days
Trial: 22055478
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition supplemented with L-glutamine (30 g) followed by calcium caseinate (30 g)
Trial: 22055478
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition with calcium caseinate (30 g) followed by L-glutamine (30 g)
Trial: 19345944
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of oral mifepristone followed 48 hours later with 400 microg of oral misoprostol, administered either at home or at the clinic
Trial: 19345944
Drug: Home administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of misoprostol
Trial: 15482522
Drug: Homogenised kiwifruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homogenised kiwifruit preparation
Trial: 11864944
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g administered every 12 hours
Trial: 8657964
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole (1 g i.v.)
Trial: 8657964
Drug: Rectal metronidazole
RxNorm normalized name: metronidazole Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal metronidazole (1 g suppository)
Trial: 8657964
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (gentamycin 80 mg i.v. + metronidazole 1 g i.v. or suppository)
Trial: 2158192
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus extract, administered intraperitoneally (i.p.)
Trial: 6451235
Drug: Nicotinamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (500 mg twice daily)
Trial: 30819520
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (120 mg)
Trial: 30819520
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone (1 mg)
Trial: 30819520
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (120 mg) in patients with nephrolithiasis
Trial: 30819520
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone (1 mg) in patients with nephrolithiasis
Trial: 28724183
Drug: Myo-Inositol-based supplement
RxNorm normalized name: myo-inositol trispyrophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-Inositol-based supplement (Folandrol®, Exeltis, Hungary) for two months and semen incubation with 2 mg/ml of Myo-Inositol for 2 hours before PICSI procedures.
Trial: 28724183
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during the same time range).
Trial: 19943918
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive nutritional care (BSNC) plus parenteral nutrition (PN)
Trial: 17299067
Drug: l-T(4) (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-T(4) (1.3 microg/kg daily) for 24 months
Trial: 7752912
Drug: 75-g fructose
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-g fructose solution with 300 mg caffeine
Trial: 7752912
Drug: 75-g glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-g glucose solution with 300 mg caffeine
Trial: 7752912
Drug: 75-g fructose
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-g fructose solution without caffeine (placebo)
Trial: 7752912
Drug: 75-g glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-g glucose solution without caffeine (placebo)
Trial: 2306439
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous indomethacin one hour beforehand
Trial: 2306439
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (comparison group)
Trial: 7002355
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg twice daily)
Trial: 7002355
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Sulfinpyrazone
Trial: 22314425
Drug: GS-5885 1
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5885 1 mg QD
Trial: 22314425
Drug: GS-5885 3
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5885 3 mg QD
Trial: 22314425
Drug: GS-5885 10
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5885 10 mg QD
Trial: 22314425
Drug: GS-5885 30
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5885 30 mg QD
Trial: 22314425
Drug: GS-5885 90
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-5885 90 mg QD
Trial: 10782903
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 14-16 mg/kg/day
Trial: 8903001
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (30 mg; i.m.)
Trial: 8903001
Drug: Dipyrone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (1.0 g; 2.5 g; i.v.)
Trial: 1853794
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic treatment
Trial: 1853794
Drug: Conventional-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose antibiotic treatment
Trial: 6191994
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg)
Trial: 30590537
Drug: Ivermectin 300
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 300 mcg/kg/day
Trial: 30590537
Drug: Ivermectin 600
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 600 mcg/kg/day
Trial: 29793404
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment for GDM
Trial: 22433473
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (520 mg/day of elemental magnesium)
Trial: 22433473
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (295.8 mg/day of elemental magnesium)
Trial: 16208149
Drug: Telmisartan (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20, 40, or 80 mg)
Trial: 10411366
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination therapy (5 mg enalapril + 5 mg felodipine ER once daily)
Trial: 10411366
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of monotherapy (10 mg enalapril once daily)
Trial: 1443507
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ketamine racemate
Trial: 1443507
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg S-(+)-Ketamine
Trial: 1443507
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg S-(+)-Ketamine after 0.1 mg/kg midazolam premedication
Trial: 29804059
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (60 mg/kg/day of DHA)
Trial: 24499206
Drug: Audio feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio feedback during stair-climbing therapy
Trial: 20838049
Drug: Permanent GES
RxNorm normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent GES implant after TPGES.
Trial: 18973936
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (1 mg twice daily)
Trial: 18973936
Drug: Montelukast (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (4 mg daily)
Trial: 12624285
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g over 30 minutes)
Trial: 3277578
Drug: Comparison treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison treatment (hospitalization without family intervention)
Trial: 31992358
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (lifestyle advice, pharmacotherapy with bulking agents or antidiarrheal medication)
Trial: 20361901
Drug: Divalproex extended
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex extended release (ER) at 15 mg/kg/d titrated to a maximum of 30 mg/kg/d
Trial: 18403559
Drug: Intravenous rtPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rtPA
Trial: 18403559
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no intravenous rtPA)
Trial: 8829858
Drug: Ketorolac 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4 mg.kg‐1 iv, repeated three times at six hour intervals
Trial: 8829858
Drug: Diclofenac 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1.0 mg.kg‐1 iv after general anaesthesia induction and 1.0 mg.kg‐1 after 12 hr
Trial: 2809260
Drug: Intraventricular gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular gentamicin therapy
Trial: 2809260
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics alone
Trial: 31790151
Drug: Aspirin added
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin added to adjuvant chemotherapy
Trial: 31790151
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to adjuvant chemotherapy
Trial: 21654128
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LDA) in high-risk group
Trial: 21654128
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LDA) in low-risk group
Trial: 7923842
Drug: Antibiotics added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics added to treatment by sinus lavage
Trial: 7923842
Drug: Sinus lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinus lavage without antibiotics
Trial: 406098
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) 29 mg
Trial: 31299067
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir monotherapy for 48 weeks
Trial: 26097039
Drug: ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ustekinumab 45 mg
Trial: 26097039
Drug: ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ustekinumab 90 mg
Trial: 26097039
Drug: ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ustekinumab 45 mg and 90 mg
Trial: 22230809
Drug: continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuation of current therapy (C group, n=20)
Trial: 15842550
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg morphine sulphate (M)
Trial: 15842550
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oxycodone hydrochloride (O)
Trial: 15842550
Drug: Combination M10/O5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination M10/O5
Trial: 15842550
Drug: Combination M7.5/O7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination M7.5/O7.5
Trial: 15842550
Drug: Combination M5/O10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination M5/O10
Trial: 15168720
Drug: Once-daily didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily didanosine (ddI)
Trial: 15168720
Drug: Twice-daily stavudine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily stavudine (d4T) plus once-daily ddI
Trial: 7808252
Drug: Overtraining group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overtraining group (OT) - exercised daily for 2 weeks at 100% of 1 RM
Trial: 2780876
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of chlorpromazine (CPZ)
Trial: 31180512
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement splint (MAS) + oral EPAP
Trial: 31180512
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement splint (MAS) + oral/nasal EPAP
Trial: 24118671
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg lomitapide on Day 1 followed by 200 mg on Day 3
Trial: 24118671
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg BID
Trial: 24118671
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin on Day 3
Trial: 11122838
Drug: Rituximab (unconjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (unconjugated anti-CD20 monoclonal antibody)
Trial: 11122838
Drug: Cytokines (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokines (e.g., interferon-alpha, interleukin-2, interleukin-12)
Trial: 11122838
Drug: Vaccine strategies
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine strategies
Trial: 9062869
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (0.5 mg at bedtime for 7 days)
Trial: 9062869
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (50 mg daily at bedtime for 37 days)
Trial: 8366176
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg cyclosporine